Literature DB >> 20304206

The future of liver transplantation.

E Varo Pérez1, J F Castroagudín.   

Abstract

Liver transplantation has been a positive impact on both the survival and the quality of life of patients with advanced liver diseases. Progressive, spectacular improvements in the results of liver transplantation have been observed since the preliminary studies by Thomas Starzl in the United States and Roy Calne in Europe. This improvement is related to better knowledge of the natural history of liver diseases, allowing more adequate recipient selection, improvement of surgical techniques, progress in postoperative management, availability of potent antibacterial, antiviral, and antifungal drugs, as well as introduction of new immunosuppressive agents and protocols. These advances have occurred in the short interval of 45 years, suggesting future improvements in the liver transplantation field. The main investigative efforts in liver transplantation have been directed as follows: First attenuation of disproprortion between the numbers of available liver grafts versus waiting list recipients, by increasing the donor pool applying bioartificial support systems, or rendering grafts compatible by the use of stem cells. Second, improved knowledge about the biology of primary liver tumors establishes indications for and optimal moments of transplantation. Third, application of individualized immunosuppressive protocols, adapted to clinical status of the recipient, as well as the development of more selective, less toxic new immunosuppressive agents. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304206     DOI: 10.1016/j.transproceed.2010.02.003

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation.

Authors:  Jun-Jun Jia; Bin-Yi Lin; Jiang-Juan He; Lei Geng; Dhruba Kadel; Li Wang; Dong-Dong Yu; Tian Shen; Zhe Yang; Yu-Fu Ye; Lin Zhou; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

2.  Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma.

Authors:  Ma Yan; Bao Dongmei; Zhang Jingjing; Jin Xiaobao; Wang Jie; Wang Yan; Zhu Jiayong
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.